We are nearing the end of finalizing our fall issue, and in just a few short weeks, we will be publishing “Institutional Corruption and the Pharmaceutical Industry.” Guest edited by Marc Rodwin, this issue addresses a much-debated issue in medicine and law: conflicts of interest (COI). The authors discuss the various sources of corruption and how each type affects medical practice, patients’ needs, public health, research, and more. Particular topics include: pharmaceutical firm dependency, pharma-sponsored research, key opinion leaders, patient advocacy organizations, drug innovation, regulating misconduct, and pharma-funded social networking websites—among many other interesting discussions. Each author takes one aspect of institutional corruption and demonstrates how it affects policy, the practice of medicine, and the broader issue of public health and safety. In addition to attracting our academic readership, this issue has also garnered lots of media interest, including Donald Light et al.’s article which was discussed in a recent article on Co.Exist.
Thank you for reading JLME. We look forward to hearing your thoughts about our fall issue!